Open-Label Study to Assess the Disposition of [14C]-LY3372689 Following Oral Administration in Healthy Male Participants
Latest Information Update: 25 Apr 2023
Price :
$35 *
At a glance
- Drugs LY 3372689 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 19 Apr 2023 Status changed from active, no longer recruiting to completed.
- 13 Apr 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 06 Mar 2023 New trial record